The importance of latent tuberculosis screening in the immunosuppressed.
Although they may not display symptoms, immunosuppressed patients are at a higher risk of progressing from latent tuberculosis infection (LTBI) to active TB disease. That’s why testing plays a vital role in finding and treating both latent and active TB.
WEBINAR
Advancing latent TB screening in immunosuppressed patients: listen to the evidence
Join our webinar live or listen on-demand as two distinguished Professors share their insights and experiences into LTBI screening and the importance of choosing the right interferon-gamma release assay.
Date: Wednesday 22 November Time: 11:30 GMT
Speakers:
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ Professor of Medicine; Chair of the Department of Infectious Diseases, Infection Control, and Employee Health; and Director of the Clinical Virology Research Program
University of Texas MD Anderson Cancer Center, Houston, TX. James Galloway
Professor of Rheumatology and Deputy Head of the atic Diseases Kings College, London.
Register here
Copyright ©2023, Revvity, Inc. All rights reserved. For a complete listing of our global offices, visit
www.revvity.com TB-UK-AD-MPN787-0001 V2 1069850
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61
